Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremie Calais

Showing results (11-20 of 207) with videos related to

Pageof 21
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 31, 2021
<sup>177</sup>Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear MedicineJohannes Czernin, Jeremie Calais
JAMA Oncology|February 17, 2022
PSMA PET in Prostate Cancer-A Biomarker or a Surrogate End Point?-ReplyThomas A Hope, Jeremie Calais
Lancet (London, England)|February 14, 2021
PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancerThomas A Hope, Jeremie Calais
European Urology Focus|February 22, 2021
We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate CancerWolfgang P Fendler, Jeremie Calais
AJR. American Journal of Roentgenology|August 7, 2020
Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Point-An Important Diagnostic, Phenotypic, and Biomarker RoleJeremie Calais, Christine E Mona
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 30, 2022
More Unacceptable Denials: Now It's PSMA-Targeted PET/CT ImagingJohannes Czernin, Thaiza Adams, Jeremie Calais
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 4, 2019
Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your RepresentativesAria Razmaria, Jeremie Calais, Johannes Czernin
European Urology|May 4, 2021
Reply to Alexa R. Meyer, Steven P. Rowe, and Nirmish Singla's Letter to the Editor re: Patrick D. McGillivray, Daiki Ueno, Aydin Pooli, et al. Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. Eur Urol 2021;79:107-11. Integrating <sup>99m</sup>Tc-sestamibi and ONEX to Optimize Risk Stratification for Renal MassesBrian Shuch, Steven Raman, Jeremie Calais
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2023
Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes CzerninMichael J Morris, Jeremie Calais, Johannes Czernin
Targeted Oncology|May 26, 2025
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand TherapyPhillip H Kuo, Jeremie Calais, Mike Crosby
Pageof 21

Showing results (11-20 of 207) with videos related to

Sort By:
Pageof 21
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 31, 2021
<sup>177</sup>Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear MedicineJohannes Czernin, Jeremie Calais
JAMA Oncology|February 17, 2022
PSMA PET in Prostate Cancer-A Biomarker or a Surrogate End Point?-ReplyThomas A Hope, Jeremie Calais
Lancet (London, England)|February 14, 2021
PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancerThomas A Hope, Jeremie Calais
European Urology Focus|February 22, 2021
We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate CancerWolfgang P Fendler, Jeremie Calais
AJR. American Journal of Roentgenology|August 7, 2020
Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Point-An Important Diagnostic, Phenotypic, and Biomarker RoleJeremie Calais, Christine E Mona
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 30, 2022
More Unacceptable Denials: Now It's PSMA-Targeted PET/CT ImagingJohannes Czernin, Thaiza Adams, Jeremie Calais
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 4, 2019
Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your RepresentativesAria Razmaria, Jeremie Calais, Johannes Czernin
European Urology|May 4, 2021
Reply to Alexa R. Meyer, Steven P. Rowe, and Nirmish Singla's Letter to the Editor re: Patrick D. McGillivray, Daiki Ueno, Aydin Pooli, et al. Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. Eur Urol 2021;79:107-11. Integrating <sup>99m</sup>Tc-sestamibi and ONEX to Optimize Risk Stratification for Renal MassesBrian Shuch, Steven Raman, Jeremie Calais
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2023
Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes CzerninMichael J Morris, Jeremie Calais, Johannes Czernin
Targeted Oncology|May 26, 2025
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand TherapyPhillip H Kuo, Jeremie Calais, Mike Crosby
Pageof 21